Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Review Article
Authors: Alamoudi, Abdullah O.
Affiliations: Department of Radiological Sciences and Medical Imaging, College of Applied Medical Sciences, Majmaah University, Almajmaah-11953, Kingdom of Saudi Arabia | Tel.: +966 561599222; E-mails: a.alamoudi@mu.edu.sa and abdullahamoudimuksa@gmail.com
Correspondence: [*] Corresponding author: Department of Radiological Sciences and Medical Imaging, College of Applied Medical Sciences, Majmaah University, Almajmaah-11953, Kingdom of Saudi Arabia. Tel.: +966 561599222; E-mails: a.alamoudi@mu.edu.sa and abdullahamoudimuksa@gmail.com.
Abstract: At present, cancer is a major health issue and the second leading cause of mortality worldwide. Researchers have been working hard on investigating not only improved therapeutics but also on early detection methods, both critical to increasing treatment efficacy and developing methods for disease prevention. Diagnosis of cancers at an early stage can promote timely medical intervention and effective treatment and will result in inhibiting tumor growth and development. Several advances have been made in the diagnostics and imagining technologies for early tumor detection and deciding an effective therapy these include radiomics, nanobodies, and aptamers. Here in this review, we summarize the main applications of radiomics, aptamers, and the use of nanobody-based probes for molecular imaging applications in diagnosis, treatment planning, and evaluations in the field of oncology to develop quantitative and personalized medicine. The preclinical data reported to date are quite promising, and it is predicted that nanobody-based molecular imaging agents will play an important role in the diagnosis and management of different cancer types in near future.
Keywords: Radiomics, medical images, PET, SPECT, nanobody, aptamers, probes, antibody, cancer
DOI: 10.3233/HAB-200436
Journal: Human Antibodies, vol. 29, no. 1, pp. 1-15, 2021
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl